PR Newswire Clinical TrialsOriginal article
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
PartnershipVANFLYTAPositive
AI Analysis
Summary
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement for commercialization of VANFLYTA in China for newly diagnosed FLT3-ITD positive AML patients. The collaboration aims to accelerate patient access to the therapy in the Chinese market.
Outcome Details
Exclusive agreement for commercialization in China
Importance:6/10
Sentiment:
0.60
partnershipexclusive agreementcommercializationChina marketoncologyAML
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 10, 2026 12:00 AM